SEARCH

SEARCH BY CITATION

References

  • 1
    Core Working Party for Asia-Pacific Consensus on Hepatitis B and C. Consensus statement on the prevention and management of hepatitis B and C in the Asia-Pacific region. J. Gastroenterol. Hepatol. 2000; 15: 82541.
  • 2
    Merican I, Guan R, Amarapuka D et al. Chronic hepatitis B virus infection in Asian countries. J. Gastroenterol. Hepatol. 2000; 15: 135661.
  • 3
    Safeary A, Beck J. Vaccination against hepatitis B: current challenges for Asian countries and future directions. J. Gastroenterol. Hepatol. 2000; 15: 396401.
  • 4
    Locarnini SA, Newbold JE. Chronic hepatitis B: the therapeutic challenge. J. Antimicrob. Chemother. 1997; 39: 55965.
  • 5
    Liaw YF. Management of patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2002; 15: 396401.
  • 6
    Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N. Engl. J. Med. 1997; 336: 34756.
  • 7
    Lok ASF, McMahon BJ. Chronic hepatitis B: update recommendations. Hepatology 2004; 39: 15.
  • 8
    Marcellin P. Advances in therapy for chronic hepatitis B. Semin. Liver Dis. 2002; 22 (Suppl. 1): 336.
  • 9
    Papatheodoridis GV, Hadziyannis SJ. Current management of chronic hepatitis B. Aliment. Pharmacol. Ther. 2004; 19: 2537.
  • 10
    Liaw YF, Leung N, Guan R, Lau GKK, Merican I. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J. Gastroenterol. Hepatol. 2003; 18: 23945.
  • 11
    Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30: 10827.
  • 12
    Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin a1 in patients with chronic type B hepatitis: a randomized controlled trial. Hepatology 1998; 27: 13837.
  • 13
    Angus PW, Hepatitis B. Weighing the costs of treatment. J. Gastroenterol. Hepatol. 2002; 17: 7378.
  • 14
    Pwu RF, Chan KA. Cost-effectiveness analysis of interferon-therapy in the treatment of chronic hepatitis B in Taiwan. J. Formos. Med. Assoc. 2002; 101: 63241.
  • 15
    Crowley SJ, Tognarini D, Desmond PV, Lees M. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000; 17: 40927.
  • 16
    Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann. Intern. Med. 1995; 122: 66475.
  • 17
    Levy P. Economic evaluation of antiepileptic drug therapy: a methodologic review. Epilepsia 2002; 43: 5508.
  • 18
    Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000; 39: 2833.
  • 19
    Evers S, Goossens M, De Vet H, Van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int. J. Technol. Assess. Health Care 2005; 21: 2405.
  • 20
    Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 1987.
  • 21
    Sculpher MJ, Pang FS, Manca A et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol. Assess. 2004; 8: 1192.
  • 22
    Antonanzas F. Transferability of economic evaluation results. Pharmacoeconomics 2004; 22: 827.
  • 23
    Nixon J, Khan KS, Kleijnen J. Summarising economic evaluations in systematic reviews: a new approach. BMJ 2001; 322: 15968.
  • 24
    Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BMG. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann. Intern. Med. 2005; 142: 82131.
  • 25
    Crowley S, Tognarini D, Desmond P, Lees M, Saal G. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J. Gastroenterol. Hepatol. 2002; 17: 15364.
  • 26
    Orlewska E. The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland. Value Health 2002; 5: 40512.
  • 27
    Buti M, Casado MA, Calleja JL, Salmeró NJ, Aguilar J, Rueda M. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. Aliment. Pharmacol. Ther. 2006; 23: 40919.
  • 28
    Sullivan SD, Veenstra DA, Chen PJ et al. Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J. Gastroenterol. Hepatol. 2006; 22: 14949.
  • 29
    He H, Yu GL. Comparing the effect and economic effectiveness of interferon alfa-1b and lamivudine in treating chronic hepatitis B. Guangdong Pharm. J. 2002; 12: 523.
  • 30
    Wei HY. Application of cost-effectiveness analysis in three therapeutic schemes for chronic hepatitis B. China Pharm. J. 2000; 11: 265.
  • 31
    Yang ZH, Chen YH. Cost-effectiveness of three therapeutic strategies for chronic hepatitis B. Acad. J. Guangdong Coll. Pharm. 2001; 17: 1356.
  • 32
    Zhang H, Wang RS, Zhang J, Kong HW, Zhu YF, Fu HB. Cost-effectiveness analysis of antiviral strategies in patients with chronic hepatitis B. Lin Chuang Hui Cui 2002; 17: 4412.
  • 33
    Zhou XQ, Wang NS, Meng J. Pharmacoeconomic study of interferon on patients with chronic hepatitis B. J. Mathemat. Med. 2004; 17: 3489.
  • 34
    Brooks EA, Lacey LF, Payne SL, Miller DW. Economic evaluation of lamivudine compared with Interferon-a in the treatment of chronic hepatitis B in the United States. Am. J. Manag. Care 2001; 7: 67782.
  • 35
    Wang RL, Ye XG. A comparison of cost-effectiveness between alpha-2b and lamivudine in treating chronic hepatitis B. Evaluat. Anal. Drug Use Hosp. China 2002; 2: 267.
  • 36
    Wu LL, Liu CX, Ying XF. The analysis of effectiveness and cost of lamivudine in treatment of chronic hepatitis. Chin. J. New Drugs 2002; 11: 81113.
  • 37
    Yan JZ. Cost-effectiveness analysis of interferon-alpha 1b with lamivudine. IMHGN 2004; 10: 589.
  • 38
    Sun X, Li YP, Zhou RL et al. Comparative effectiveness of lamivudine monotherapy for patients with chronic hepatitis B. Proceedings of ISPOR, the 2nd Asian Pacific Conference; 5–7 March 2006, Shanghai, China.
  • 39
    Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 2003; 337: 173345.